SCHEMBL22393144

SCHEMBL22393144

CC1(C)O[C@H]2[C@H](n3cnc4c(N)ncnc43)O[C@](F)(COP(=O)(OCc3ccccc3)OCc3ccccc3)[C@H]2O1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ P2RX3 P56373 3/20 0.46
▸ P2RX4 Q99571 3/20 0.46
▸ P2RX1 P51575 1/20 0.46
▸ PI4KA P42356 1/20 0.45
▸ PI4K2B Q8TCG2 1/20 0.45
▸ PI4K2A Q9BTU6 1/20 0.45
▸ PI4KB Q9UBF8 1/20 0.45
▸ AHCY P23526 3/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.44
▸ P2RY12 Q9H244 5/20 0.44
▸ P2RY2 P41231 2/20 0.43
▸ P2RY1 P47900 1/20 0.43
▸ P2RX7 Q99572 1/20 0.42
▸ AMD1 P17707 2/20 0.41
▸ NT5E P21589 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26937509 0.93 P2RX3 (0.46) P2RX3P2RX4P2RX1PI4KAPI4K2B
SCHEMBL26361754 0.93 P2RX3 (0.46) P2RX3P2RX4P2RX1PI4KAPI4K2B
SCHEMBL22402669 0.91 P2RX3 (0.48) P2RX3P2RX4P2RX1PI4KAPI4K2B
SCHEMBL24205185 0.91 P2RX3 (0.48) P2RX3P2RX4P2RX1PI4KAPI4K2B
SCHEMBL23922252 0.90 P2RX3 (0.46) P2RX3P2RX4P2RX1PI4KAPI4K2B
SCHEMBL24205188 0.89 P2RX3 (0.46) P2RX3P2RX4P2RX1PI4KAPI4K2B
SCHEMBL22393028 0.86 P2RY12 (0.42) P2RY12P2RY2P2RY1
SCHEMBL26937515 0.85 P2RX1 (0.57) P2RX3P2RX4P2RX1PI4KAPI4K2B
SCHEMBL22392931 0.85 P2RX1 (0.57) P2RX3P2RX4P2RX1PI4KAPI4K2B
SCHEMBL26361760 0.85 P2RX1 (0.57) P2RX3P2RX4P2RX1PI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124511-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) 2024-04-18 — — US disclosed
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-12-12 — — US disclosed
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-10-03 — — US disclosed
US-20220017560-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 WUXI PHARMATECH HEALTHCARE FUND I L.P. (CN) 2022-01-20 — — US disclosed
US-20210403501-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 SHANGHAI XINQI WU FILM AND TELEVISION INVESTMENT CO., LTD. (CN) 2021-12-30 — — US disclosed
US-11186606-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2021-11-30 — — US disclosed
US-11149051-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2021-10-19 — — US disclosed
US-20200283468-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 LUMINEX INTERNATIONAL (CN) 2020-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017560-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 PHKA1, PHKA2, PRKCA P2RX3 1233/4885P2RX4 2015/4885P2RX1 885/4885
US-11186606-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RX3 1233/4885P2RX4 2015/4885P2RX1 885/4885
US-20200283468-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 PHKA1, PHKA2, PRKCA P2RX3 1233/4885P2RX4 2015/4885P2RX1 885/4885
US-11149051-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RX3 1233/4885P2RX4 2015/4885P2RX1 885/4885
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RX3 1233/4885P2RX4 2015/4885P2RX1 885/4885
US-20240124511-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 PHKA1, PHKA2, PRKCA P2RX3 1233/4885P2RX4 2015/4885P2RX1 885/4885
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA P2RX3 1233/4885P2RX4 2015/4885P2RX1 885/4885
US-20210403501-A1 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 PHKA1, PHKA2, PRKCA P2RX3 1233/4885P2RX4 2015/4885P2RX1 885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback